Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.
Alemtuzumab
Multiple sclerosis
Risk estimation
Secondary autoimmune disorders
Thyroid autoimmunity
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
27
06
2019
revised:
19
07
2019
accepted:
24
07
2019
pubmed:
3
8
2019
medline:
16
1
2020
entrez:
3
8
2019
Statut:
ppublish
Résumé
Alemtuzumab is approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab-related secondary autoimmune disorders (sAID) are common, with thyroid sAID being the most frequent, and fundamentally affect the risk-benefit ratio. Therefore, biomarkers indicating the development of sAID are urgently needed to instruct clinical decisions. We evaluated whether the anti-thyroid autoantibodies (ThyAb) anti-thyroglobulin (anti-TG) and anti-thyroid-peroxidase (anti-TPO) detected at baseline by standard testing are able to indicate increased risk for thyroid sAID following alemtuzumab treatment in a multicentre prospective cohort of 106 alemtuzumab-treated RRMS patients. We here present an interim-analysis with a median follow-up of 36 months. Baseline characteristics demonstrated no significant differences between patients with or without thyroid sAID. 29/106 (27·4%) patients developed thyroid sAID between 5 and 51 months following alemtuzumab treatment initiation. 14/29 patients (48·3%) were positive for ThyAb at baseline and developed thyroid sAID. Hazard ratio for time to thyroid autoimmunity was 12.15 (95% CI 4.73-31.2) indicating a highly increased risk for ThyAb positive patients. Baseline ThyAb were associated with shorter time to sAID, but not with a specific disease entity of thyroid sAID. Hazard ratios for age, sex, previous treatment, disease duration, disability and smoking status demonstrated no significant association with thyroid autoimmunity. Standard ThyAb-testing for anti-TPO and anti-TG antibodies at baseline was able to indicate increased risk for clinically manifest thyroid sAID and should therefore be used in clinical decisions concerning alemtuzumab treatment initiation. FUND: German Ministry of Education, Science, Research and Technology and the German Research foundation.
Sections du résumé
BACKGROUND
BACKGROUND
Alemtuzumab is approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab-related secondary autoimmune disorders (sAID) are common, with thyroid sAID being the most frequent, and fundamentally affect the risk-benefit ratio. Therefore, biomarkers indicating the development of sAID are urgently needed to instruct clinical decisions.
METHODS
METHODS
We evaluated whether the anti-thyroid autoantibodies (ThyAb) anti-thyroglobulin (anti-TG) and anti-thyroid-peroxidase (anti-TPO) detected at baseline by standard testing are able to indicate increased risk for thyroid sAID following alemtuzumab treatment in a multicentre prospective cohort of 106 alemtuzumab-treated RRMS patients. We here present an interim-analysis with a median follow-up of 36 months.
FINDINGS
RESULTS
Baseline characteristics demonstrated no significant differences between patients with or without thyroid sAID. 29/106 (27·4%) patients developed thyroid sAID between 5 and 51 months following alemtuzumab treatment initiation. 14/29 patients (48·3%) were positive for ThyAb at baseline and developed thyroid sAID. Hazard ratio for time to thyroid autoimmunity was 12.15 (95% CI 4.73-31.2) indicating a highly increased risk for ThyAb positive patients. Baseline ThyAb were associated with shorter time to sAID, but not with a specific disease entity of thyroid sAID. Hazard ratios for age, sex, previous treatment, disease duration, disability and smoking status demonstrated no significant association with thyroid autoimmunity.
INTERPRETATION
CONCLUSIONS
Standard ThyAb-testing for anti-TPO and anti-TG antibodies at baseline was able to indicate increased risk for clinically manifest thyroid sAID and should therefore be used in clinical decisions concerning alemtuzumab treatment initiation. FUND: German Ministry of Education, Science, Research and Technology and the German Research foundation.
Identifiants
pubmed: 31371192
pii: S2352-3964(19)30504-3
doi: 10.1016/j.ebiom.2019.07.062
pmc: PMC6711888
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Autoantibodies
0
anti-thyroglobulin
0
Alemtuzumab
3A189DH42V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-386Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Références
J Clin Invest. 2009 Jul;119(7):2052-61
pubmed: 19546505
Eur J Endocrinol. 2011 Jan;164(1):107-13
pubmed: 20956436
J Clin Endocrinol Metab. 2011 Sep;96(9):E1466-71
pubmed: 21715532
Neuroepidemiology. 2012;39(2):135-42
pubmed: 22889755
J Clin Endocrinol Metab. 2014 Jan;99(1):80-9
pubmed: 24170099
J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):795-8
pubmed: 24368840
J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):208-15
pubmed: 24849515
Int J Mol Sci. 2015 Jul 20;16(7):16414-39
pubmed: 26204829
Curr Opin Obstet Gynecol. 2015 Dec;27(6):406-15
pubmed: 26485458
Neurology. 2017 Sep 12;89(11):1107-1116
pubmed: 28835401
Neurology. 2017 Sep 12;89(11):1117-1126
pubmed: 28835403
Front Neurol. 2017 Oct 30;8:569
pubmed: 29163335
Neurology. 2018 May 1;90(18):849-851
pubmed: 29602914
Mult Scler. 2018 Nov;24(13):1783-1784
pubmed: 30307361
Thyroid. 2018 Dec;28(12):1682-1693
pubmed: 30351224
Neurology. 2018 Dec 11;91(24):e2233-e2237
pubmed: 30404783
J Neurol. 2019 Jun;266(6):1405-1411
pubmed: 30863891
Clin Endocrinol (Oxf). 1995 Jul;43(1):55-68
pubmed: 7641412